Clinical Trial Search

Primary: Number of Participants With Postoperative Intra-abdominal Abscess — 6; 8 Participants

Primary: Percentage of Participants With Abstinence for the Last 4 Weeks of Treatment From Weeks 9-12 — 15.31; 8.72; 5.64 percentage of participants — p=0.0027

Primary: QTcB Change — 416.50; 416.41; 418.39; 423.27 ms

Primary: Number of Participants With Complete Response (CR), No PONV Symptoms, Nausea — 8; 25; 24; 28 Participants

Primary: Change in Insulin Stimulated Glucose Disposal Over 12 Week Study Period — 0.76 mg/kg lean body mass/minute — p=0.2068

Primary: Pathologic Complete Response Rate of Sunitinib — 0 Participants

Primary: Median Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Level — 125 IU/mL

Primary: Percentage of Subjects With Progression-free Survival — 7.5; 15.0 percentage of subjects

Primary: Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease in the Ovarian Cancer and Breast Cancer Cohorts…

Primary: Montgomery-Asberg Depression Rating Scale Comparison to Baseline — 29.50; 15.83 units on a scale

Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants

Primary: Number of Participants With Solid Tumor Response ≥ 16 Weeks for Based Upon Local Investigator Assessments — 0; 3; 16; 71 Participants

Primary: Overall Response Rate (ORR): Proportion of Subjects Achieving the Best Overall Responses of Complete Response (CR) or Partial Response (PR) — 51; 15 Participants

Primary: Number of Participants With Treatment-free Remission at 1 Year After Study Completion — 2 Participants

Primary: Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months — -3.83 standard uptake value ratio